Rankings
▼
Calendar
AKBA Q1 2025 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
$365M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$57M
+75.8% YoY
Gross Profit
$50M
86.7% margin
Operating Income
$14M
23.6% margin
Net Income
$6M
10.7% margin
EPS (Diluted)
$0.03
QoQ Revenue Growth
+23.3%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$14M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$310M
Total Liabilities
$286M
Stockholders' Equity
$25M
Cash & Equivalents
$113M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$57M
$33M
+75.8%
Gross Profit
$50M
$30M
+66.3%
Operating Income
$14M
-$15M
+190.5%
Net Income
$6M
-$18M
+134.0%
Revenue Segments
Product
$56M
97%
License Collaboration And Other Revenue
$2M
3%
← FY 2025
All Quarters
Q2 2025 →